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Abstract
The objective of this study is to determine the vaccine effectiveness (VE) of the pentavalent 
rotavirus vaccine (RV5) for preventing rotavirus-related hospitalizations and emergency 
department (ED) visits during the 2006–07 and 2007–08 rotavirus seasons using two study 
designs. Active, prospective population-based surveillance was conducted to identify cases of 
laboratory-confirmed rotavirus-related hospitalizations and ED visits to be used in case-cohort and 
case-control designs. VE was calculated using one comparison group for the case-cohort method 
and two comparison groups for the case-control method. The VE estimates produced by the three 
analyses were similar. Three doses of RV5 were effective for preventing rotavirus-related 
hospitalizations and ED visits in each analysis, with VE estimated as 92% in all three analyses. 
Two doses of RV5 were also effective, with VE ranging from 79% to 83%. A single dose was 
effective in the case-cohort analysis, but was not significant in either of the case-control analyses. 
The case-cohort and the case-control study designs produced the same VE point estimates for 
completion of the three dose series. Two and three doses of RV5 were effective in preventing 
rotavirus-related hospitalizations and ED visits.
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1. Introduction
Rotavirus is the most common cause of diarrhea-related illness and death among infants and 
young children [1]. Prior to the introduction of a rotavirus vaccine in the United States (US), 
nearly all children were infected with rotavirus during the first five years of life [2–5]. The 
introduction of a three dose, oral, pentavalent, human-bovine reassortant vaccine (RV5) 
(RotaTeq, Merck and Co. Inc., Whitehouse Station, NJ), in the US led to significant 
reductions in rotavirus hospitalizations and emergency department (ED) visits [6–12]. RV5, 
which contains G1–G4 and P8 strains, was licensed for use in the US in February 2006 and 
subsequently recommended by the Centers for Disease Control and Prevention (CDC)’s 
Advisory Committee on Immunization Practices and the American Academy of Pediatrics 
for routine use in infants [13,14]. RV5 is recommended for infants at 2, 4 and 6 months of 
age, and all doses should be administered before a child reaches 32 weeks of age [15]. 
Coverage with ≥1 dose of RV5 reached 50–60% during the first year following its 
introduction in 2006 and increased steadily (2.7% per quarter on average) to 74% by 
mid-2009 [6].
Because vaccine effectiveness (VE) may be reduced under field conditions [16], post-
licensure evaluation of VE is important. Different study designs have been used to estimate 
post-licensure VE and each has advantages and disadvantages. While case-control studies 
are most frequently used to determine post-licensure VE [17–27], the case-cohort design is 
also used for this purpose [28–33]. The vaccination status of diseased cases is compared to 
disease-free controls with the traditional case-control design, and to a representative 
subcohort from the community regardless of disease status that produced the cases with the 
case-cohort design. A direct comparison of these designs for rotavirus VE has not been 
done.
As part of the CDC-funded New Vaccine Surveillance Network (NVSN), seasonal, 
population-based acute gastroenteritis (AGE) surveillance was conducted to determine the 
burden and epidemiology of rotavirus disease and to monitor the impact of the rotavirus 
vaccine program. This system provided a unique opportunity to determine the effectiveness 
of RV5 for preventing rotavirus-associated hospitalizations and ED visits using two different 
study designs.
2. Materials and methods
Active, prospective, population-based surveillance for hospitalizations and ED visits due to 
AGE in non-immunocompromised children <3 years was conducted during two rotavirus 
seasons: 2007 (December 2006–June 2007) and 2008 (December 2007–June 2008). 
Surveillance sites included University of Rochester Medical Center (Monroe County, New 
York), Cincinnati Children’s Hospital Medical Center (Hamilton County, Ohio) and 
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Vanderbilt University Medical Center (Davidson County, Tennessee), hereafter referred to 
as “Rochester”, “Cincinnati”, and “Nashville”. Institutional Review Board approvals were 
obtained from the CDC and study sites. Details of NVSN AGE surveillance have been 
previously described [34,35].
2.1. Identification of rotavirus-positive inpatient and ED cases
Surveillance for hospitalized children occurred five days each week. In the ED, systematic 
sampling was performed 2–4 days each week for 10–12 h. Bulk stool samples were obtained 
within 14 days of the child’s visit for AGE symptoms (>95% collected within 7 days) and 
tested using Rotaclone, a commercial enzyme immunoassay (EIA) by Meridian Bioscience, 
Inc. Rotavirus-positive samples were genotyped by reverse transcription polymerase chain 
reaction and nucleotide sequencing [36–39]. To be eligible as cases, children were required 
to have a laboratory-confirmed rotavirus-related hospitalization or ED visit, birth on or after 
April 1, 2006, and age of ≥52 days at symptom onset (old enough to have received one dose 
of RV5 with two weeks for an immune response).
2.2. Identification of comparison groups
Two study designs, a case-cohort design with one comparison group and a case-control 
design with two comparison groups, were used to calculate the VE in three separate 
analyses.
2.2.1. Comparison group #1: subcohort comparison group (case-cohort 
design)—The first comparison group was a representative subcohort of children registered 
with primary care practices in each of the three counties. Probability proportional to size 
(PPS) cluster sampling was used to select a representative subcohort from each county [40]. 
Subcohort children were required to be county residents, active members of their practice 
(≥1 visit during the first seven months of life), have a date of birth on or after April 1, 2006 
and not be immunocompromised.
2.2.2. Comparison group #2: AGE controls (case-control design)—The second 
comparison group consisted of children with AGE, found rotavirus-negative by EIA, who 
were enrolled using the same surveillance protocol during the same timeframe and at the 
same medical institutions as the rotavirus-positive cases.
2.2.3. Comparison group #3: acute respiratory infection (ARI) controls (case-
control design)—The third comparison group consisted of children enrolled in NVSN 
active surveillance for ARI during the same timeframe and at the same medical institutions 
as the rotavirus-positive cases. Subjects enrolled in both the AGE and ARI surveillance 
systems were excluded, thus reducing the potential for misclassification of cases and 
controls. Details of NVSN ARI surveillance have been previously described [17,41–43].
2.3. Determination of vaccination status
Parents were asked to provide names of all health care providers where their children 
received immunizations and documentation of the immunization record (electronic or 
written) was requested. In addition, state immunization registries were queried for 
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documentation of immunizations. For subcohort subjects, the subjects’ practices were 
visited and medical charts were reviewed for vaccination documentation. For all subjects, 
administration dates and types of rotavirus vaccine were obtained.
2.4. Statistical analyses
All analyses were conducted using SAS, version 9.3 (SAS Institute Inc., Cary, North 
Carolina). Significance was defined as P < 0.05, and all P values were 2-sided.
2.4.1. Case-cohort design—VE was calculated for 1, 2 and 3 doses of RV5 against 
laboratory-confirmed rotavirus-related hospitalizations and ED visits. Vaccination status and 
number of days spent at risk during rotavirus season were included as time-dependent 
variables. Time between rotavirus seasons (July–November 2007) was not considered time 
at risk since rotavirus rarely circulates during those months [10]. Other covariates included 
date of birth, insurance status, and breastfeeding status. RV5 doses given <14 days before 
failure (onset of rotavirus symptoms) or censoring were not included, as it takes two weeks 
for vaccine-induced immunity to fully develop. Subjects entered the risk set at the beginning 
of the rotavirus season or, if <52 days of age at the beginning of the season, at 52 days of 
age, and the time axis was age at failure or censoring. There were no subjects selected as 
members of the subcohort who were also identified by NVSN surveillance as a rotavirus-
positive case. A stratified Cox model using study site as the strata variable was used to 
estimate the adjusted hazard ratio for a rotavirus-related hospitalization or ED visit in 
vaccinated subjects relative to unvaccinated subjects, with the following formula: VE = (1 − 
Adjusted Hazard Ratio) × 100. Ninety-five percent confidence intervals (CI) were calculated 
using the robust sandwich estimator to account for intra-cluster correlation resulting from 
PPS cluster sampling [44].
2.4.2. Case-control designs using AGE and ARI controls—In both case-control 
analyses, cases were matched to a variable number of controls (1–5) according to date of 
birth (±30 days). Controls were also time-matched to cases at failure time (i.e. controls were 
matched to a case if they visited the hospital or ED on or after the date that their matched 
case failed). Doses a control received after the failure date of its matched case were not 
included, and age was calculated as age at the matched case’s failure date. In a small number 
of instances (1 AGE control and 4 ARI controls), the control visited the hospital or ED 
before their matched case. The assumption was made that these controls did not receive 
vaccine in the short period (<6 weeks) between their own visit and their matched case’s 
visit. This assumption allowed us to match all 76 cases to at least one control. In each 
instance that this occurred, the matched control was >9 months of age at their visit, so it is 
unlikely that they would have received vaccine following their visit. In the instance that a 
control did receive vaccine following their visit, the bias is toward the null. In the event that 
a child had multiple visits during which they were enrolled by surveillance within the same 
season, only their initial visit was included in this study. None of the rotavirus-positive cases 
had multiple visits within the same season. Conditional logistic regression was used to 
calculate VE for 1, 2 or 3 doses of RV5 with the following formula: VE = (1 − Adjusted 
Odds Ratio) × 100. RV5 doses given <14 days before the onset of rotavirus symptoms for 
the cases were not included. For controls, RV5 doses given <14 days before the date of their 
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matched case’s symptom onset were not included. Covariates included age, breastfeeding 
status, insurance status and site.
3. Results
3.1. Demographics
3.1.1. Cases—Seventy-six cases met the surveillance enrollment inclusion criteria, and 
had verified vaccination status; 21 from Rochester, 39 from Cincinnati, and 16 from 
Nashville. Table 1 displays the characteristics of the cases compared to each of the 
comparison groups.
3.2. VE using the case-cohort design and subcohort comparison group (comparison group 
#1)
3.2.1. Comparison group #1: subcohort comparison group (case-cohort 
design)—The subcohort consisted of 21 clusters (10 children each) from Rochester, 39 
clusters from Cincinnati, and 16 clusters from Nashville. After removing subcohort 
members not meeting inclusion criteria and/or those excluded due to a missing chart or 
vaccination verification (N = 17), there were 743 subjects included: 204 from Rochester, 386 
from Cincinnati and 153 from Nashville. Table 1 compares the demographic characteristics 
of the cases and subcohort groups. Compared to cases, subcohort subjects were more likely 
to be privately insured (P < 0.0001) and to have ever been breastfed (P < 0.001).
3.2.2. Comparison of diphtheria, tetanus and acellular pertussis vaccine 
(DTaP) vaccination status and practices of the cases and subcohort 
(comparison group #1)—To assess whether cases had the same opportunity to receive 
RV5 as subcohort subjects, the first DTaP vaccination status was compared; 99% of cases 
and 93% of subcohort subjects received an initial DTaP (P = 0.0505). There was no 
difference in age at first DTaP (9 weeks for both groups) (P = 0.3291). To determine 
whether the selected clusters represented the practices from which the cases arose, the 
practices of the cases and subcohort were compared. Five of the 21 cases from Rochester 
(24%), 17 of the 39 cases from Cincinnati (44%) and 4 of the 16 cases from Nashville (25%) 
were from practices that had at least one cluster in the study.
3.2.3. VE results using the case-cohort design and subcohort comparison 
group (comparison group #1)—The initial multivariable Cox model included a time-
dependent vaccination status variable, a time-dependent variable for number of days spent in 
a rotavirus season, date of birth, gender, insurance status (public or none versus private) and 
breastfeeding status (ever breastfed). Gender was removed due to its insignificant effect on 
VE. The recommended, three-dose course of RV5 was 92% (95% CI: 60%, 99%) effective 
in preventing rotavirus-related hospitalizations and ED visits. Two doses of RV5 vaccine 
were 81% (95% CI: 9%, 96%) effective, and one dose was 77% (95% CI: 14%, 94%) 
effective (Table 2).
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3.3. VE using the case-control design (comparison groups #2 and #3)
3.3.1. Comparison group #2: matched AGE controls—There were 873 children 
born on or after April 1, 2006, screened by AGE surveillance. Of these, 714 (82%) were 
enrolled. Controlling for site, clinical setting (inpatient or ED) and enrollment year, non-
enrolled children were less likely to have insurance (P < 0.05), but there were no significant 
differences by age or gender. Major reasons for non-enrollment included refusal (37%), lack 
of interpreter (35%), and absence of a parent or legal guardian (11%). Of those enrolled by 
AGE surveillance, 331 were eligible for this study, and 314 had their rotavirus vaccination 
history verified. Of these 314, there were 179 AGE controls matched to a rotavirus-positive 
case. Matched AGE controls were similar to cases with regard to all demographic factors 
(Table 1).
3.3.2. Comparison group #3: matched ARI controls—There were 2129 children 
born on or after April 1, 2006, screened by ARI surveillance. Of these, 1284 (60%) were 
enrolled. After controlling for site, clinical setting and enrollment year, there were no 
significant differences between enrolled and non-enrolled children except non-enrolled 
children were less likely to have insurance (P < 0.01). Major reasons for non-enrollment 
included protocol deviation at the Cincinnati site (48%), refusal (20%) and lack of 
interpreter (14%). Of those enrolled by ARI surveillance, 896 were eligible for this study, 
and 871 had their rotavirus vaccination history verified. Of these 871, there were 288 ARI 
controls matched to a rotavirus-positive case. ARI controls were more likely to be publicly 
insured compared to cases (P = 0.02), and the proportion of subjects from each site differed 
between ARI controls and rotavirus-positive cases (P = 0.02) (Table 1).
3.3.3. VE results using the case-control design (comparison groups #2 and 
#3)—Both of the initial conditional logistic regression models (matched on the case’s 
failure time and ±30 days on date of birth) included: vaccination status, insurance status, 
breastfeeding status, gender, site and age (at failure for cases, and at time of the matched 
cases’ failures for controls). Though cases were matched to controls ±30 days on date of 
birth and exactly on the cases’ failure dates, age remained significant in the multivariable 
model. Therefore, age was retained in the final model in order to completely control for any 
residual confounding not completely controlled for by matching. In both models, gender was 
removed due to its insignificant effect on VE. In the model using AGE controls (comparison 
group #2), the VE in preventing rotavirus-related hospitalization and ED visits for 3, 2, and 
1 dose was 92% (95% CI: 21%, 99%), 83% (95% CI: 17%, 96%), and 68% (95% CI: −18%, 
91%), respectively. In the model using ARI controls (comparison group #3), the VE for 3, 2, 
and 1 dose was 92% (95% CI: 33%, 99%), 79% (95% CI: 9%, 95%), and 58% (95% CI: 
−38%, 87%), respectively (Table 2).
3.4. Genotype distribution of cases and VE against strains G1–G4
Genotype distribution of the cases varied by year (Table 3). In general, point estimates for 
VE against serotypes G1–G4 were similar to VE estimates against all serotypes (Table 4).
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This is the first study to evaluate the VE of RV5 using two study designs and three 
comparison groups with the same set of rotavirus-positive cases. Each of the VE methods 
found three doses of RV5 to be 92% effective in preventing rotavirus-related 
hospitalizations and ED visits with similar point estimates for partial doses. Our three-dose 
VE estimates were comparable to the pre-licensure efficacy trial (94.5%) [45], and similar to 
other post-licensure RV5 VE studies using case-control designs [21–23,27,46,47].
As part of a population-based surveillance system, cases in our study were selected to 
represent affected individuals in a defined county population, and the subcohort was selected 
to represent the county population. The Cox model allows for time-dependent variables, 
making it possible to consider the changing vaccination status as children receive multiple 
rotavirus vaccinations and more precisely accounting for the timing and dose effects relative 
to the disease incidence [48]. This approach is advantageous for VE studies since the 
vaccination status of children changes over time.
Despite the advantages of using a case-cohort design, certain limitations also exist. The 
process of selecting a representative subcohort and verifying immunizations can be costly 
and time-consuming. Because PPS sampling was used to select clusters, intracluster 
correlation was present. Our model did correct for design effects from our clustering 
methodology, thus the likelihood that this introduced a significant source of bias in our study 
is low. Another potential limitation is the varying propensity to seek medical care, which 
may differ among families who do and do not have their children vaccinated [49]. However, 
the likelihood of a bias relating to propensity to seek care may be lower in a study such as 
ours which reflects a somewhat serious outcome (e.g. hospitalization or an emergency 
department visit). Subcohort subjects were required to be active patients in their practice, 
which may have introduced a selection bias resulting in participating subjects being better 
vaccinated than those considered ineligible. To examine this, we reviewed the literature and 
found that following the RV5 recommendation in February 2006, coverage with ≥1 dose of 
vaccine among infants aged 5 months rose quickly to about 50–60% within the first year 
[50]. In our subcohort, of the 40 children born in September 2006, who would have been 5 
months of age in February 2007, 19 (47.5%) had received at least one dose of RV5 before 5 
months of age. Therefore, we do not feel as though this inclusion criterion resulted in our 
subcohort being significantly better vaccinated than the actual cohort. Also, no difference 
existed in the age of the first DTaP dose for cases and subcohort subjects, which suggests 
that this bias was not present. DTaP, however, may not be the best measure of vaccination 
availability for a newly introduced vaccine such as RV5 [6]. Unfortunately, we did not have 
enough specific details for each of the practices to know whether there were differences in 
RV5 availability and provider recommendations. Finally, although the subcohort group 
theoretically should have best represented the source population from which the rotavirus-
positive cases arose, it appears to have been the least similar to the rotavirus-positive cases 
in terms of demographics. One study concluded that a subcohort selected to be 
representative of the community from which hospitalized or ED cases arose was 
demographically less similar to the cases than test-negative controls enrolled in the hospital 
or ED, and that a case-cohort study design may not be optimal for determining post-
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licensure VE [30]. All subjects were required to be residents of surveillance counties, in 
which 95% of all pediatric hospital admissions are served by NVSN surveillance hospitals. 
Therefore, if subcohort subjects required hospitalization, they likely had access to these 
surveillance hospitals.
Demographically, the AGE control group (comparison group #2) was the most comparable 
of the three comparison groups to the cases. Since AGE controls were enrolled using the 
same surveillance system that identified rotavirus-positive cases, studies utilizing AGE 
controls would likely be less expensive than studies using the other two comparison groups. 
A potential bias with this method is that AGE controls may be misclassified if there are 
issues with the sensitivity or specificity of the rotavirus EIA results. In our study 
misclassification is unlikely to have substantially impacted our results since the rotavirus 
EIA is reported to be >95% sensitive, and >95% of bulk stool specimens were collected 
within 7 days [51]. Lastly, non-enrolled children were less likely to have insurance 
compared with enrolled children, so our analysis may under-represent the non-insured, 
which may be a less well-vaccinated population.
The case-control design utilizing ARI controls (comparison group #3) provided a 
comparison group that was demographically more similar to the cases than the subcohort, 
but less similar than the AGE controls. Since ARI controls did not have AGE, 
misclassification of cases and controls is unlikely. While ARI subjects were enrolled using a 
surveillance system of children in the same age group as the AGE subjects, the distribution 
of age and children over the seasons differed. Similar to the AGE analysis, non-enrolled 
children were less likely to have insurance compared with enrolled children, so this study 
population may under-represent the noninsured, a potentially less well-vaccinated 
population. We found no advantage to using ARI controls over AGE controls.
In our study the case-cohort design produced VE point estimates similar to those produced 
by the more traditional case-control designs. This finding differs from two studies evaluating 
influenza VE, where a case-cohort method had substantially lower VE than the case-control 
method using the same cases [17,30]. For influenza vaccination, propensity to seek care may 
be more important than for rotavirus vaccination in which the cases and subcohort subjects 
were more closely aligned, perhaps making the case-cohort analysis more robust.
RV5 was found to be highly effective in preventing rotavirus-related hospitalizations and 
ED visits and, despite methodologically specific strengths and weaknesses, both the case-
cohort and case-control study designs produced the same VE point estimates for a three-dose 
vaccination course of RV5.
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Table 2
Comparison of vaccine effectiveness against laboratory-confirmed rotavirus-related hospitalizations and 
emergency department visits using three types of comparison groups in infants and young children from 
Rochester, Cincinnati and Nashville, 2007–2008.










Three doses 92% (60%, 99%) 92% (21%, 99%) 92% (33%, 99%)
Two doses 81% (9%, 96%) 83% (17%, 96%) 79% (9%, 95%)
One dose 77% (14%, 94%) 68% (−18%, 91%) 58% (−38%, 87%)
Abbreviations: CI, confidence intervals; VE, vaccine effectiveness.
a
Adjusted for number of days at risk (time-dependent), date of birth, insurance status and breastfeeding status.
b
Matched ±30 days on date of birth and adjusted for age, breastfeeding, insurance status and site.
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Table 4
Comparison of vaccine effectiveness against laboratory-confirmed rotavirus-related hospitalizations and 
emergency department visits caused by strains G1–G4 using three different comparison groups in infants and 
young children from Rochester, Cincinnati and Nashville, 2007–2008.










Three doses 89% (3–99%) 91% (12–99%) d
Two doses 78% (−31–96%) 85% (14–98%) 82% (−21–97%)
One dose 66% (−41–92%) 61% (−65–91%) 41% (−141–85%)
Abbreviations: CI, confidence intervals; VE, vaccine effectiveness.
a
Adjusted for number of days at risk (time-dependent), date of birth, insurance status, breastfeeding status and gender.
b
Matched ±30 days on date of birth and adjusted for age, breastfeeding, insurance status and gender.
c
Matched ±30 days on date of birth and adjusted for age, breastfeeding, insurance status, site and gender.
d
Three-dose estimate could not be calculated as the single case strain G1–G4 case with three doses was matched to a single control with three 
doses.
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